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B cells are the primary producers of immuno-
globulin and play a critical role in adaptive immu-
nity (Mauri and Bosma, 2012). The maintenance 
of proper B cell output from early hematopoi-
etic progenitors, along with the production of 
an appropriate antibody repertoire, is critical to 
maintaining the balance between normal im-
mune function and diseases such as autoimmunity 
and cancer. Therefore, B lymphopoiesis requires 
the intricate interplay of many different tran-
scription factors in a complex gene regulatory 
network that controls lineage specification and 
commitment (Matthias and Rolink, 2005; Nutt 
and Kee, 2007; Mandel and Grosschedl, 2010). 
Antigen-independent B cell development be-
gins with the differentiation of lymphoid primed 
multipotent progenitors to common lymphoid 
progenitors (CLPs), a process driven by the 
expression of PU.1 and Ikaros (Matthias and 
Rolink, 2005; Nutt and Kee, 2007), both of 
which may play a role in regulating Flt3 and 
IL-7R expression (DeKoter et al., 2002; Yoshida 
et al., 2006). These early progenitors also express 
Rag1 and Rag2, and thus begin the process of 
rearrangement of the Ig heavy chain (IgH) locus 
(Igarashi et al., 2002). Lineage specification to 
the next stages of B cell development, the 
prepro–B cell and pro–B cell, involves the up-
regulation of several genes controlled by E2A 
and Ebf1 (O’Riordan and Grosschedl, 1999), 
including Pax5 (Cobaleda et al., 2007). Pax5 is 
essential for B cell lineage commitment, as it 
represses genes that are inappropriate for B cell 
development (Souabni et al., 2002). The tran-
sition to pre–B cells, the stage at which Ig light 
chain (IgL) rearrangement begins, and immature 
B cells, involves many factors, including Sox4 
(Sun et al., 2013), which has also been implicated 
in regulating the expression of the Rag genes 
(Mallampati et al., 2014).
MicroRNAs, a class of small noncoding 
RNAs that negatively regulate gene expression, 
are key posttranscriptional regulators of hema-
topoietic cell fate decisions and immunity 
(O’Connell et al., 2010b). Several microRNAs 
regulate key checkpoints in B cell development, 
and the loss of a microRNA processing protein, 
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MicroRNAs have emerged as key regulators of B cell fate decisions and immune function. 
Deregulation of several microRNAs in B cells leads to the development of autoimmune 
disease and cancer in mice. We demonstrate that the microRNA-212/132 cluster (miR-
212/132) is induced in B cells in response to B cell receptor signaling. Enforced expression 
of miR-132 results in a block in early B cell development at the prepro–B cell to pro–B cell 
transition and induces apoptosis in primary bone marrow B cells. Importantly, loss of miR-
212/132 results in accelerated B cell recovery after antibody-mediated B cell depletion. 
We find that Sox4 is a target of miR-132 in B cells. Co-expression of SOX4 with miR-132 
rescues the defect in B cell development from overexpression of miR-132 alone, thus 
suggesting that miR-132 may regulate B lymphopoiesis through Sox4. In addition, we show 
that the expression of miR-132 can inhibit cancer development in cells that are prone to  
B cell cancers, such as B cells expressing the c-Myc oncogene. We have thus uncovered 
miR-132 as a novel contributor to B cell development.
© 2015 Mehta et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 o
n
 Septem
ber 21, 2015
jem.rupress.org
D
ow
nloaded from
 
Published September 14, 2015
http://jem.rupress.org/content/suppl/2015/09/10/jem.20150489.DC1.html 
Supplemental Material can be found at:
1680 miR-212/132 regulates B cell development | Mehta et al.
RESULTS
The microRNA-212/132 cluster is induced in B cells  
in response to BCR activation
To investigate the role of the microRNA-212/132 cluster 
(miR-212/132) in B cells, we first examined the expression 
of miR-212/132 in various sorted splenic and bone marrow 
cell populations obtained from WT C57BL/6 mice. RNA was 
extracted from these cells, and then we performed TaqMan 
qPCR to profile microRNA expression. We initially found 
that miR-212/132 was not significantly enriched in either the 
splenic or bone marrow CD19+ B cell population; however, 
we found a significant up-regulation of miR-132 in these cells 
at 24 h in response to stimulation with mouse anti-IgM, which 
binds to and activates the BCR (Fig. 1 A). This induction 
peak could be replicated by stimulation with PMA and iono-
mycin, but not with activation of NF-B through TLR ligands 
or anti-CD40, suggesting the induction requires multiple path-
ways downstream of BCR signaling, whereas NF-B alone is 
insufficient (Fig. 1, A–C). The level of miR-132 induction 
demonstrated a strong dependence on the concentration of 
anti-IgM used for stimulation (Fig. 1 D).
Enforced expression of microRNA-132 inhibits  
B cell development
To understand the function of the miR-132/212 cluster on 
B cell development, we examined the effects of enforced ex-
pression of either miR-132 or miR-212 on B cell development. 
Bone marrow from WT C57BL/6 mice that was enriched for 
hematopoietic stem and progenitor cells (HSPCs) was retro-
virally transduced with control vector (WTMG) or a miR-132 
overexpression vector (WTmiR-132). These cells were then 
used to reconstitute the immune system of lethally irradiated 
C57BL/6 WT recipients, and we subsequently tracked the 
development of B cells. We found that WTmiR-132 mice had 
a significant depletion in the frequency and total number of 
peripheral blood B cells compared with WTMG controls at 
Dicer, results in a block in the pro–B to pre–B cell transition 
(Koralov et al., 2008). In particular, both miR-150 and miR-
34a regulate this transition by targeting c-Myb and Foxp1, 
respectively (Xiao et al., 2007; Zhou et al., 2007; Rao et al., 
2010). Another example is miR-148a, which regulates plasma 
cell differentiation by targeting Bach2 (Porstner et al., 2015). 
In addition, miR-181 and miR-155 play an important role 
in B cell immune function by targeting AID to regulate class-
switching and somatic hypermutation (Thai et al., 2007; 
de Yébenes et al., 2008; Teng et al., 2008). Importantly, de-
regulation of the expression of many microRNAs important in 
B cell development and function results in autoimmunity (Xiao 
et al., 2008) and the onset of B cell cancers (Eis et al., 2005; 
Costinean et al., 2006; Calin et al., 2008; Xiao et al., 2008; 
Puissegur et al., 2012).
Recently, the microRNA-212/132 cluster (miR-212/132) 
has emerged as an important regulator of hematopoietic stem 
cell function (Mehta et al., 2015), antiviral immunity (Lagos 
et al., 2010), macrophage and TH17 T cell immune function 
(Taganov et al., 2006; Shaked et al., 2009; Nahid et al., 2013; 
Nakahama et al., 2013), and inflammation and proliferation 
during wound healing (Li et al., 2015). In addition, it has 
been shown that miR-132 plays a role in the proliferation 
and invasion of certain solid tumors (Zhang et al., 2014; Jiang 
et al., 2015), as well as in pathological angiogenesis (Anand 
et al., 2010), thus making it a potential candidate for cancer 
therapeutics. Recently, several groups have also shown miR-
212/132 to be deregulated in certain B cell cancers (Lawrie 
et al., 2008; Pede et al., 2013; Tavolaro et al., 2015). In this 
study, we uncover a novel role for miR-212/132 as a regula-
tor of early B cell development by targeting the transcription 
factor Sox4. In addition, we find that miR-132 induces 
apoptosis in B cells and that this may be leveraged to inhibit 
the progression of B cell cancers, such as B cell lymphomas in 
mice expressing the c-Myc oncogene driven by the IgH en-
hancer (Langdon et al., 1986).
Figure 1. miR-132 is induced in B cells in response to BCR signaling. (A) Relative miR-132 expression in primary splenic B cells stimulated with anti-
IgM (aIgM; 5 µg/ml), LPS (20 µg/ml), CD40L (2 µg/ml), IL-4 (10 ng/ml), or CpG (0.5 µM) for the indicated durations. miR-132 expression was detected using 
TaqMan RT-qPCR (n = 3). (B) Relative expression of miR-212 in splenic B cells stimulated with LPS (20 µg/ml) or anti-IgM (5 µg/ml) for the indicated times  
(n = 3). (C) Relative expression of miR-132 in splenic B cells stimulated for 8 h with a combination of PMA (15 ng/ml), ionomycin (0.5 µg/ml), and anti-IgM  
(5 µg/ml), as indicated (n = 3). (D) Relative expression of miR-132 in splenic B cells stimulated for 8 h with varying concentrations of anti-IgM as indicated  
(n = 3). Data represent two independent experiments and are represented as mean ± SEM. ***, P < 0.001, Student’s t test.
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To better understand the influence of miR-212/132 in 
early B cell commitment, we profiled the expression of miR-
132 in B cell progenitors. We found an enrichment in miR-
132 in progenitor B (pro–B) cells and precursor B (pre–B) cells 
compared with total bone marrow cells and CLPs (Fig. 3 A). 
To investigate the consequence of this, we analyzed Hardy 
fractions in the bone marrow of WTmiR-132 and WTMG mice 
(Rumfelt et al., 2006). We found that WTmiR-132 mice had a 
comparable frequency of CLPs and an elevation in precursor–
progenitor B (prepro–B) B cells (Hardy Fr. A) compared 
with WTMG mice (Fig. 3 B). However, we found a significant 
3–4 mo after reconstitution (Fig. 2, A and B). This was ac-
companied by a decrease in the total number of leukocytes 
(CD45+), B cells (CD19+), and plasma cells (CD138+) in the 
spleen of WTmiR-132 mice (Fig. 2, C and D). The loss of B cells 
was dramatically mirrored in the bone marrow compartment 
(Fig. 2 E), where a minor increase in myeloid cells was also 
observed (Fig. 2 F). A similar depletion in total leukocytes, 
B cells, and T cells was observed in the spleen of mice at 9 mo 
after reconstitution (Fig. 2 G). The bone marrow compartment 
of these mice also demonstrated a loss in B cells and T cells, 
but no change in myeloid cells was apparent (Fig. 2 H).
Figure 2. Enforced expression of miR-132 in mice alters B cell development. WT C57BL/6 mice were lethally irradiated and reconstituted with 
donor HPSCs expressing either a control (MG) or a miR-132–overexpressing (miR-132) vector. (A–F) Mice were analyzed at 4 mo after reconstitution (n = 
10–12 mice per group). (A) Frequency of peripheral blood B cells (B220+) in MG and miR-132 mice. (B) Total number of peripheral blood B cells (B220+)  
in MG and miR-132 mice. (C) Total number of leukocytes (CD45+) and B cells (CD19+) in the spleen of MG and miR-132 mice. (D) Total number of plasma 
cells (CD138+) in the spleen of MG and miR-132 mice. (E) Total number of B cells (CD19+) in the bone marrow of MG and mIR-132 mice. (F) Total number 
of myeloid cells (CD11b+) and granulocytes (Gr-1+) in the bone marrow of MG and miR-132 mice. (G–H) miR-132 and MG mice analyzed at 9 mo after 
reconstitution. (G) Total number of leukocytes (CD45+), B cells (CD19+), and T cells (CD3e+) in the spleen of MG and miR-132 mice. (H) Total number of  
B cells (CD19+) and T cells (CD3e+) in the bone marrow of MG and miR-132 mice. Data represent at least two independent experiments and are represented  
as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test.
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among the two microRNAs in the miR-212/132 cluster, as 
a more relevant regulator of B cell biology.
Loss of the microRNA-212/132 cluster enhances B cell 
development under nonhomeostatic conditions
A close examination of the peripheral blood, spleen, and bone 
marrow of miR-212/132/ and WT mice at 16-wk of age 
revealed no significant difference in the frequency of B cells 
present in these compartments (Fig. 4, A–C). To further un-
derstand the contribution of miR-212/132 to pro–B cell de-
velopment, we challenged WT and miR-212/132/ mice 
with an anti-CD20 antibody to deplete all mature B cells 
(Sarikonda et al., 2013) and track B cell development under 
nonhomeostatic conditions. We observed a rapid depletion 
decrease in the frequency of both pre–B cells (Hardy Fr. BC) 
and pro–B cells (Hardy Fr. C’) in the bone marrow of 
WTmiR-132 mice (Fig. 3 B), suggestive of a developmental block 
between the prepro–B cell to pro–B cell transition. An alter-
native surface marker characterization of these B cell pro-
genitor populations resulted in similar findings (Fig. 3, C–E). 
Enforced expression of miR-212 alone resulted in a decrease 
in B cells in the bone marrow compartment at 4 mo after re-
constitution; however, no changes in the frequency of bone 
marrow B cell progenitors or splenic B cells was observed 
compared with controls (Fig. 3, F–H). Because miR-132 was 
more strongly induced in B cells, and its enforced expression 
in HSPCs produced a stronger effect on B cell development 
compared with that of miR-212, we chose to examine miR-132, 
Figure 3. miR-132 causes a block in early B cell 
development. (A) miR-132 expression in various bone 
marrow B cell progenitor populations. Cells were sorted 
by FACS directly into RNA lysis buffer and miR-132 ex-
pression was detected using TaqMan RT-qPCR (n = 2). 
(B–E) Analysis of MG and miR-132 mice at 4 mo after 
reconstitution (n = 10–12 mice per group). (B) Hardy 
fractions for B cell progenitor populations in the bone 
marrow of MG and miR-132 mice. Populations were 
gated on lineage-negative cells (CD3, Ter119, Ly6C, Gr1, 
CD11b), and are presented as follows: CLP (lineage-
CD19-CD24-CD43medCD93hiIgM-B220-cKit+IL7Ra+), Fr. A 
(prepro–B; lineageB220+CD43+CD19CD24CD93+cKit+
IL7Ra+), Fr. BC (pro–B; lineageB220+CD43+CD19+CD24med
CD93+), and Fr. C’ (pre–B; lineageB220+CD43+CD19+ 
CD24hiCD93+). (C) Frequency of CLPs using alternative 
surface markers (lineagecKit+Sca1+Flt3+IL7Ra+) in the 
bone marrow MG and miR-132 mice. (D) Frequency  
of pro–B cells using alternative surface markers 
(B220+IgMCD43+CD24+) in the bone marrow of MG and 
miR-132 mice. (E) Frequency of pre–B cells using alter-
native surface markers (B220+IgMCD43) in the bone 
marrow of MG and miR-132 mice. (F–H) WT C57BL/6 
mice were lethally irradiated and reconstituted with do-
nor HPSCs expressing either a control (MG) or a miR-
212–overexpressing (miR-212) vector. Mice were 
analyzed at 4 mo after reconstitution (n = 4–5 mice per 
group). (F) Frequency of B cells (B220+) in the bone mar-
row of MG and miR-212 mice. (G) Frequency of pro–B 
cells (B220+IgMCD43+CD24+) in the bone marrow of 
MG and miR-212 mice. (H) Frequency of pre–B cells 
(B220+IgMCD43) in the bone marrow of MG and  
miR-212 mice. Data represent at least two independent 
experiments and are represented as mean ± SEM.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test.
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Figure 4. miR-212/132 regulates B cell apoptosis and the loss of miR-212/132 alters B cell development under nonhomeostatic conditions.  
(A–C) miR-212/132/ (KO) and WT mice were analyzed at 12–16 wk of age to understand the physiological contribution of miR-212/132 on B cell output  
(n = 7–10 mice per group). (A) Frequency of B cells (CD19+) in the peripheral blood of KO and WT mice. (B) Frequency of B cells (CD19+) in the spleen of KO and 
WT mice. (C) Frequency of B cells (CD19+) in the bone marrow of KO and WT mice. (D–G) 16-wk old KO and WT mice were treated with either an anti-CD20 anti-
body (30 µg/mouse) or PBS (n = 3–4 mice per group). (D) Graph indicates the frequency of B cells (B220+) in the peripheral blood at each of the indicated time 
points after anti-CD20 antibody treatment. (E) Frequency of Annexin V+ cells within the peripheral blood B cell (CD19+) population 12 h after anti-CD20 treat-
ment. (F) Frequency of cells in each Hardy fraction for each experimental group 42 d after anti-CD20 treatment. (G) Frequency of bone marrow B cells (CD19+) in 
each experimental group 42 d after anti-CD20 treatment. (H) 6-mo-old KO and WT mice were treated with 9 evenly spaced LPS (1 mg/kg of body weight) or PBS 
injections over one month. Graphs shows the total number of B cells (CD19+) in the spleen after the last injection. (I) Frequency of bone marrow CD19+ cells from 
MG and miR-132 mice that demonstrated positive staining for Annexin V and 7-AAD. (J) KO and WT splenic B cells were isolated and cultured in vitro for the 
indicated durations. Graph demonstrates the frequency of Annexin V+ cells at each time point. (K) KO or WT splenic B cells were cultured in the presence of no 
stimulation, or with LPS (20 µg/ml) or CpG (0.5 µM). Proliferation of these cells was measured at the indicated time points using the WST-1 cell proliferation assay. 
Data represents two independent experiments and is represented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test.
 o
n
 Septem
ber 21, 2015
jem.rupress.org
D
ow
nloaded from
 
Published September 14, 2015
1684 miR-212/132 regulates B cell development | Mehta et al.
clustering analysis of differentially expressed genes revealed 
that WT and miR-212/132/ cells from the same time points 
were more closely related to each other than to any other 
sample (Fig. 5 A). Among the genes that were differentially 
regulated between WT and miR-212/132/ cells at the 
same time point, there was enrichment for genes related to 
B cell apoptosis and pre–B cell differentiation, as well as viral 
response genes (Fig. 5 C). These included genes such as Rag1, 
Sfrp1, Eif2ak2, Irf7, Mx1, and Rsad2. Importantly, we found 
enrichment in the expression of several miR-132 targets in 
miR-212/132/ B cells compared with WT B cells, including 
the transcription factor Sox4, a known regulator of B cell de-
velopment (Laurenti et al., 2013; Sun et al., 2013; Mallampati 
et al., 2014).
We have previously shown that Sox4 mRNA expression 
levels are decreased in the bone marrow of WTmiR-132 mice 
compared with WTMG controls (Mehta et al., 2015). Sox4 
has a conserved, computationally predicted 7mer-m8 bind-
ing site for miR-132 (Fig. 6 A). We thus validated that it is a 
direct target of miR-132 and explored the possibility that 
miR-132 may regulate B cell development through Sox4. 
We transfected HEK293T cells with a construct that overex-
pressed miR-132 in the presence of a luciferase reporter im-
mediately upstream of either the 3UTR of Sox4, the 3UTR 
of Sox4 with a mutated miR-132 binding site, or an irrele-
vant 3UTR (control). Compared with the control vector, 
we found decreased expression of luciferase using the con-
struct with an intact Sox4 3UTR and restored luciferase ex-
pression with the mutated miR-132–binding site (Fig. 6 B). 
We found a significant decrease in Sox4 mRNA and protein 
expression levels in purified bone marrow B cells from 
WTmiR-132 mice when compared with WTMG controls (Fig. 6, 
C and D). Consistent with this, we found an elevation in Sox4 
transcript expression in bone marrow B cells from miR-
212/132/ mice compared with WT mice after 42 d of anti-
CD20 treatment (Fig. 6 E).
Although it is known that a complete loss of Sox4 has 
dramatic consequences on B cell development, we explored 
whether a partial decrease in Sox4 protein levels, as might be 
expected by up-regulation of a microRNA, may alter B cell 
fate. To do this, we reconstituted lethally irradiated C57BL/6 
mice with HSPC-enriched bone marrow cells transduced 
with either a control vector (WTMG) or a vector expressing 
an shRNA knockdown for Sox4 (WTshSOX4) using a strategy 
previously described (Chaudhuri et al., 2012). WTshSOX4 mice, 
when compared with WTMG controls, demonstrated a signif-
icant depletion in the frequency of B cells in the spleen (Fig. 6 F) 
and bone marrow compartment (Fig. 6 G) at 4 mo after re-
constitution. Although we observed no change in the frequency 
of prepro–B cells, there was a significant decrease in the fre-
quency of pro–B cells (Fig. 6 H) and pre–B cells (Fig. 6 I) in 
the bone marrow of WTshSOX4 mice.
To determine if overexpression of miR-132 may alter 
B cell development genes upstream of SOX4, we looked at 
the expression of early regulators of B cell fate in bone marrow 
B cells from WTMG and WTmiR-132 mice. We found a decrease 
of peripheral blood B cells in all mice treated with anti-CD20 
compared with control mice treated with PBS (Fig. 4 D). We 
found, however, that KO mice had a slower depletion in 
B cells compared with WT mice, evidenced in the frequency 
of peripheral blood B cells 1 d after anti-CD20 treatment 
(Fig. 4 D). Consistent with this, peripheral blood B cells in 
KO mice had lower levels of apoptosis, measured by Annexin 
V expression, than WT mice 12 h after anti-CD20 treatment 
(Fig. 4 E). Within 3 d, the total number of B cells in both 
anti-CD20–treated cohorts was <1% of the total number of 
peripheral blood leukocytes. Interestingly, under these con-
ditions, miR-212/132/ mice demonstrated a more rapid 
rebound in the frequency of peripheral blood B cells compared 
with WT mice 42 d after anti-CD20 treatment (Fig. 4 D). 
A closer examination of the bone marrow compartment of 
these mice at 42 d revealed that KO mice had increased fre-
quencies of pro–B cells (Hardy Fr. BC), pre–B cells (Hardy 
Fr. C’), and total B cells (CD19+) compared with WT mice 
after treatment with anti-CD20 (Fig. 4, F and G). This indi-
cates a unique advantage of miR-212/132/ B cell progeni-
tors to replenish the B cell pool under conditions of stress. We 
further corroborated this result by treating miR-212/132/ 
and WT mice with serial LPS injections to mimic aging under 
conditions of inflammatory stress (Esplin et al., 2011). Con-
sistent with the aforementioned result, we found that miR-
212/132/ mice showed a large accumulation of B cells in 
the spleen compared with WT mice (Fig. 4 H).
The microRNA-212/132 cluster regulates B cell survival
We next sought to investigate whether miR-132 may influence 
B cell development by altering the survival or proliferation of 
B cells. We found that primary splenic B cells in WTmiR-132 at 
2 mo after reconstitution demonstrated increased cell death 
compared with WTMG controls, as measured by Annexin V 
staining (Fig. 4 I), indicating that overexpression of miR-132 
results in increased apoptosis in B cells in these mice. We next 
cultured primary splenic B cells from miR-212/132/ and 
WT mice with or without anti-IgM, and found in both 
conditions miR-212/132/ B cells were more resistant to 
apoptosis (Fig. 4 J), consistent with the potential role of miR-
212/132 in regulating cell death. Importantly, we found no 
difference in proliferation of splenic B cells from miR-212/ 
132/ or WT mice in unstimulated conditions or in the pres-
ence of TLR ligands (Fig. 4 K).
Sox4 is a direct target of microRNA-132 in B cells
Seeking to better understand the underlying molecular mecha-
nism for this defect in B cell development in WTmiR-132 mice, 
we began by performing RNA-seq analysis on immature 
B cells obtained from WT and miR-212/132/ mice under 
steady-state conditions, and after 8 or 20 h of anti-IgM stim-
ulation. We found several differentially expressed genes be-
tween samples (Fig. 5 A and Table 1). These were enriched 
for genes related to cell death, calcium ion transport, BCR 
signaling, and cytokine production when comparing anti-IgM–
stimulated cells to unstimulated cells (Fig. 5 B). As expected, 
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Co-expression of Sox4 with microRNA-132 rescues 
defective B cell development with enforced expression  
of microRNA-132 alone
We next sought to investigate if Sox4 is the key target of 
miR-132 responsible for regulating B cell development. To 
in Rag1 expression levels, though not statistically significant, 
in purified bone marrow B cells from WTmIR-132 when com-
pared with WTMG cells, but observed no changes in the ex-
pression levels of other genes critical for B cell development, 
including PU.1, Ikxf1, Ebf11, E2A, and Pax5 (Fig. 7).
Figure 5. Stimulation of miR-212/132/ and WT B cells through the BCR results in dramatic gene expression changes. B cells were purified 
from miR-212/132/ and WT mice and subsequently either left unstimulated or stimulated for 8 or 20 h with anti-IgM (5 µg/ml). RNA was harvested 
from the cells and processed for RNA-sequencing. (A) Heat map and clustering indicating the number of differentially expressed genes between  
each sample. (B) Functional annotations for differentially expressed genes between WT-stimulated B cells (8 or 20 h with anti-IgM) compared with 
WT unstimulated B cells. (C) Enriched functional annotations for genes differentially expressed between miR-212/132/ and WT B cells at any of the 
time points.
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of Sox4 and miR-132 in the respective samples by qPCR 
(Fig. 8, A and B). Surprisingly, we found that 38% of MIG-
SOX4 mice and 31% of MIG-SOX4-miR-132 mice suc-
cumbed to an aggressive leukemia, characterized by markedly 
enlarged spleens and lymph nodes (Fig. 8, C and D). The 
cellular origin of these leukemias appeared variable, with 22% 
showing B cell infiltration in the lymph nodes (Fig. 8 E) and 
78% showing a severe myeloid cell infiltration in the lymph 
do this, we attempted to rescue the defect in B cell develop-
ment observed with enforced expression of miR-132 by co-
expressing Sox4 that lacks the miR-132–binding site in the 
same cells. We reconstituted mice with HSPCs expressing an 
empty vector (WTMIG), or with a vector expressing either 
miR-132 only (WTmiR-132), Sox4 only (WTSOX4), or miR-132 
and Sox4 together (WTmiR-132-SOX4) using a strategy previ-
ously described (Rao et al., 2010). We validated the expression 
Figure 6. Sox4 is a direct target of miR-132 and is a key regulator of B cell development. (A) Schematic of the predicted miR-132–binding site 
in the SOX4 3 UTR. (B) Relative luciferase expression in HEK293T cells transfected with a miR-132 overexpression vector and either a vector containing 
luciferase only (control), luciferase and the Sox4 3 UTR immediately downstream (Sox4 3 UTR), or a vector containing luciferase and a Sox4 3 UTR with 
a mutated miR-132–binding site (SOX4 3 UTR mut; n = 5). (C) Sox4 transcript expression level, obtained by RT-qPCR, in B cells purified from the bone 
marrow of MG and mIR-132 mice (n = 3). (D) SOX4 protein expression levels, obtained by Western blot, in B cells purified from the bone marrow of MG 
and mIR-132 mice. (E) Sox4 transcript expression in B cells from WT and miR-212/132/ (KO) mice 42 d after treatment with anti-CD20 (n = 5). (F–I) WT 
C57BL/6 mice were lethally irradiated and reconstituted with donor bone marrow cells transduced with either a control (MG) or SOX4 shRNA expressing 
(shSOX4) retroviral vector. Mice were analyzed at 4 mo after reconstitution (n = 4–5 per group). (F) Frequency of B cells (CD19+) in the spleen of MG and 
shSOX4 mice. (G) Frequency of B cells (B220+) in the bone marrow of MG and shSOX4 mice. (H) Frequency of pro–B cells in the bone marrow of MG and 
shSOX4 mice. (I) Frequency of pre–B cells in the bone marrow of MG and shSOX4 mice. Data represents two independent experiments and is represented 
as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test.
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a significant improvement in survival compared with mice 
receiving E-myc cells with the control vector (Fig. 9 B). 
Importantly, surviving mice that received E-myc donor cells 
expressing miR-132 demonstrated a rescue in the frequency 
of CD19+ B cells, CD11b+ myeloid cells and pre–B cells in the 
bone marrow compartment compared with mice that received 
E-myc donor cells with the control vector (Fig. 9, C–E). 
Thus, the expression of miR-132 had a protective effect on 
cancer occurrence in mice that were given E-myc cells pre-
disposed to forming B cell cancers.
DISCUSSION
A handful of microRNAs have been implicated in regulating 
hematopoietic cell fate decisions, including B cell lineage 
commitment (Xiao et al., 2007; O’Connell et al., 2010b; Rao 
et al., 2010). As posttranscriptional regulators of gene expres-
sion, these microRNAs primarily serve to fine-tune the ex-
pression of their targets, and in turn confer robustness to 
biological processes (Ebert and Sharp, 2012). When deregu-
lated, however, microRNAs can tip the balance between 
normal and pathological function of a cell. In this study, we 
have uncovered a novel role for miR-212/132 in regulating 
the differentiation of prepro–B cells to pro–B cells by target-
ing the transcription factor Sox4. We found that deregulating 
miR-132 in vivo can affect survival of B cells and inhibit 
growth of certain B cell cancers.
We observed that miR-212/132 is highly induced in 
B cells in response to BCR activation, but not to activation 
of TLR receptors or CD40, which results in a strong NF-B 
response. This highlights a potentially unique regulation of 
miR-212/132 in B cells, independent of what has been ob-
served in macrophages, where a significant, but less dramatic 
induction of miR-212/132 has been observed with TLR4 
stimulation (Taganov et al., 2006; Shaked et al., 2009). Im-
portantly, this induction was replicated by stimulation with 
PMA, a DAG analogue, but not with ionomycin, which mim-
ics Ca2+ influx into a cell, thus suggesting that miR-212/132 
may be regulated by CREB or a host of other factors in B cells, 
as has been observed in neurons (Klein et al., 2007; Wen 
et al., 2010).
nodes (Fig. 8 F). Importantly, we found that the cells in those 
mice with B cell infiltration did not express surface markers 
characteristic of early B cell progenitors.
Analysis of the peripheral blood of mice lacking obvious 
disease at 3 mo after reconstitution revealed that co-expression 
of Sox4 partially rescues the loss of B cells observed with ex-
pression of miR-132 alone (Fig. 8 G), thus suggesting that 
miR-132 regulates B cell development in part by altering the 
expression of Sox4. An examination of early B cell progenitors 
by looking at Hardy fractions in the bone marrow of these 
mice was supportive of this finding. We found a partial nor-
malization of the frequency of prepro–B cells (Fr. A), pro–B 
cells (Fr. BC), and pre–B cells (Fr. C’) in MIG-SOX4-mIR-
132 mice compared with MIG-miR-132 mice (Fig. 8 H).
MicroRNA-132 protects E-myc mice from B cell  
leukemia development
Several groups have shown that the microRNA-212/132 
cluster is deregulated in certain leukemias of B cell origin (Pede 
et al., 2013; Tavolaro et al., 2015). Given our observation 
that miR-212/132 inhibits B cell development and induces 
B cell apoptosis, we asked if it could inhibit the growth of 
B cell leukemias/lymphomas. To this end, we overexpressed 
miR-132 in 70Z/3 cells, a pre–B cell lymphoblastic tumor 
cell line, and found increased Annexin V+ staining in cells 
expressing miR-132 compared with a control vector (Fig. 9 A). 
We next investigated whether delivering miR-132 to bone 
marrow cells from mice with a c-Myc transgene driven by an 
IgH enhancer (E-myc mice; Langdon et al., 1986) could 
prevent the spontaneous occurrence of B cell cancers. To do 
this, we reconstituted lethally irradiated WT C57BL/6 mice 
with HSPC-enriched bone marrow cells from WT or E-myc 
mice that were transduced with either a control vector or a 
miR-132–expressing vector. Over 6 mo, mice reconstituted 
with WT cells had no incidence of cancer. However, 75% of 
mice that received cells from E-myc donors expressing the 
control vector developed spontaneous B cell lymphomas or 
leukemias and succumbed to disease (Fig. 9 B). Although 
42% of the mice receiving E-myc donor cells transduced 
with a miR-132 expression vector also succumbed, there was 
Figure 7. Enforced expression of miR-132 does not alter expression of B cell development genes upstream of SOX4. Transcript expression 
levels of (A) PU.1, (B) Ikzf1, (C) EBF1, (D) E2A, (E) PAX5, and (F) Rag1 obtained by RT-qPCR from B cells purified from the bone marrow of MG and miR-132 
mice (n = 3). Data represents two independent experiments and is represented as mean ± SEM.
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response to BCR signaling, one may also hypothesize a 
potential role in B cell immune function. In fact, several 
microRNAs, such as miR-155, miR-181b, and miR-125b, 
have been shown to modulate immature and germinal center 
B cell function (de Yébenes et al., 2008; Teng et al., 2008; 
Porstner et al., 2015).
To investigate whether the role of miR-212/132 in B cell 
development is physiological, we analyzed miR-212/132/ 
mice. We found that miR-212/132/ B cells that were more 
resistant to apoptosis. In addition, miR-212/132/ mice had 
an increased output of B cells compared with WT mice under 
nonhomeostatic conditions, such as when B cells were de-
pleted with a mouse anti-CD20 antibody. This role of miR-
212/132 in buffering B cell output under conditions of stress 
is consistent with the role of microRNAs in conferring ro-
bustness to many biological processes (Ebert and Sharp, 2012). 
To investigate the developmental consequence of miR-
212/132 up-regulation in B cells, we enforced expression of 
miR-132 in the bone marrow compartment of mice. We 
found that this enforced expression blocks the development 
of pro–B cells, which express the pre-BCR. Thus, it remains 
to be seen whether miR-212/132 may be induced by pre-
BCR signaling and what role this may play in the develop-
mental process. Our results are consistent with the critical 
role of microRNAs in the transition to pro–B and pre–B 
cells, as has been evidenced in mice with a genetic deletion of 
Dicer (Koralov et al., 2008). To date, this remains the earliest 
stage in B cell development at which a microRNA regulates 
B cell fate. Two other microRNAs, miR-150 and miR-34a, 
regulate the pro–B to pre–B cell transition by targeting c-Myb 
and Foxp1, respectively (Xiao et al., 2007; Zhou et al., 2007; 
Rao et al., 2010). Given the strong induction of miR-132 in 
Figure 8. Co-expression of SOX4 rescues the defect in B cell development with expression of miR-132 alone. WT C57BL/6 mice were lethally 
irradiated and reconstituted with donor bone marrow cells expressing either a control (MIG), a miR-132–overexpressing (MIG-miR-132), a SOX4-overex-
pressing (MIG-SOX4), or a SOX4- and miR-132–overexpressing (MIG-SOX4-miR-132) retroviral vector (n = 5 mice per group). (A) Validation of miR-132 
overexpression in donor HSPCs transduced with the labeled constructs. (B) Validation of SOX4 expression in donor HSPCs transduced with the labeled 
constructs. (C) Representative spleens from MIG, MIG-miR-132, MIG-SOX4, and MIG-SOX4-miR-132 mice at 4 mo after reconstitution. (D) Select LNs 
from MIG and MIG-SOX4 mice. Red arrows point to examples of enlarged LNs in MIG-SOX4 mice. (E) Frequency of B cells in LNs of MIG-SOX4 and MIG-
SOX4-miR-132 mice with marked B cell expansion. (F) Frequency of myeloid cells in LNs of MIG-SOX4 and MIG-SOX4-miR-132 mice with marked myeloid 
cell expansion. (G) Frequency of bone marrow B cells in MIG, MIG-miR-132, MIG-SOX4, and MIG-SOX4-miR-132 mice at 4 mo after reconstitution. 
(H) Hardy fractions from the above cohorts of mice. Data represents the combination of two independent experiments and is represented as mean ± SEM. 
*, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test.
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development. This may be done by co-expression of membrane-
bound IgM in the E-myc background (Nussenzweig et al., 
1988). Importantly, as was observed in primary B cells, the 
delivery of miR-132 to 70Z/3 cells, a B cell cancer line, in-
duced apoptosis in these cells. We note, however, that this 
contrasts the role of miR-132 promoting pathological angio-
genesis (Anand et al., 2010).
Our work also led to the discovery of Sox4 as a novel tar-
get for miR-132. We demonstrated that Sox4 is a key player 
in mediating the B cell development defect observed with 
miR-132 overexpression. A genetic deletion of Sox4 in mice 
has been shown to completely abolish the development of 
pro–B cells (Sun et al., 2013). Consistent with this, we found 
a dramatic loss of pro–B cells with miR-132 overexpression 
and a concomitant increase in B cell apoptosis. Importantly, 
we demonstrated that subthreshold levels of Sox4, either by 
miR-132 overexpression or by shRNA knockdown of Sox4, 
are sufficient to recreate the defect in pro–B cell development. 
We found that overexpression of miR-132 also affected down-
stream targets of Sox4 (Mallampati et al., 2014), particularly 
Rag1. Co-expression of Sox4 with miR-132 almost completely 
rescued the B cell developmental defect observed with ex-
pression of miR-132 alone. In particular, the frequency of 
prepro–B (Fr. BC) and pro–B (Fr. C’) cells was replenished in 
the bone marrow of mice overexpressing both Sox4 and miR-
132 compared with mice overexpressing miR-132 alone. 
We have recently shown that this microRNA cluster helps 
maintain normal hematopoietic stem cell output with age by 
buffering Foxo3 protein levels (Mehta et al., 2015). The cur-
rent study demonstrates that miR-212/132 maintains B cell 
output through a different mechanism, serving more as a 
gatekeeper that modulates Sox4 protein levels when increased 
B cell output is required.
Aging the miR-212/132 mice did not reveal the occur-
rence of B cell cancers; however, it’s possible deregulation of 
miR-212/132 may aid in the progression of cancers once 
they have been established. In fact, it has been demonstrated 
that miR-212/132 is deregulated in cancers of various forms, 
including B cell leukemias, and that up-regulation of miR-
212/132 in lung cancers inhibits proliferation and progres-
sion of the disease (Pede et al., 2013; Zhang et al., 2014; Jiang 
et al., 2015; Tavolaro et al., 2015). We found that enforced 
expression of miR-132 in donor cells from E-myc mice, 
which are prone to develop pre–B and immature B cell lym-
phomas and leukemias, had a strong protective effect on cancer 
development. This model suggests that enforced expression of 
miR-132 decreases the number of cells susceptible to becoming 
cancerous, primarily by decreasing the number of pre–B cells 
in the bone marrow compartment. Consistent with this, pre-
vious studies have demonstrated that the incidence of B cell 
lymphomas can be decreased in E-myc mice by enhancing 
the transition out of the pre–B cell stage to later stages of B cell 
Figure 9. Enforced expression of miR-
132 inhibits the development of sponta-
neous B cell cancers in cells with the 
E-myc transgene. (A) Cells from a pre–B 
cell lymphoblastic leukemia line, 70Z/3, were 
transduced with a control vector (MGP) or a 
miR-132–overexpressing vector (miR-132) and 
cultured for 48 h with or without LPS (20 µg/ml). 
The frequency of cells expressing AnnV was 
then measured by FACS. (B–E) C57BL/6 mice 
were reconstituted with donor HSPCs from 
WT or E-myc mice that were either trans-
duced with a control vector (MG) or miR-132 
overexpressing vector (miR-132). These mice 
were followed for 4 mo and harvested for 
analysis at this time point (n = 8–10 mice per 
group). (B) Survival curve for all experimental 
cohorts (P = 0.0037). Frequency of (C) bone 
marrow B cells (CD19+), (D) myeloid cells 
(CD11b+), and (E) pre–B cells (B220+IgM-
CD43-) in all cohorts. Data represents two 
independent experiments and is represented 
as mean ± SEM. **, P < 0.01; ***, P < 0.001, 
Student’s t test.
 o
n
 Septem
ber 21, 2015
jem.rupress.org
D
ow
nloaded from
 
Published September 14, 2015
1690 miR-212/132 regulates B cell development | Mehta et al.
FACSAria IIu cell sorter (BD) at the Caltech Flow Cytometry Core Facility 
after surface staining with fluorescent antibodies for B220, CD19, CD43, 
CD24, IgM, CD11b, CD3e, Gr-1, Ter119, Nk1.1, Sca1, cKit, Flt3, and 
IL7Ra (BioLegend). RNA was then harvested from these cells using the 
miRNAeasy RNA prep kit (QIAGEN).
Expression profiling and qPCR. RNA harvested from the respective cell 
populations was analyzed as previously described (Chaudhuri et al., 2012) by 
real-time qPCR (RT-qPCR) with a 7300 Real-Time PCR machine (Ap-
plied Biosystems). We used TaqMan MicroRNA Assays (Life Technologies) 
for miR-132, miR-212 and snoRNA-202 (control) to perform TaqMan 
qPCR as per manufacturer’s instructions. We performed SYBR Green–based 
RT-qPCR for mRNA expression of mouse Sox4, Ikzf1, Ebf1, E2A, Pax5, 
PU.1, and Rag1 after cDNA synthesis using qScript cDNA SuperMix 
(Quanta) and detection with PerfeCTa qPCR Fastmix with ROX (Quanta) 
as per manufacturer’s instructions. Table S3 lists primers used for qPCR.
Luciferase reporter assays. We performed luciferase assays for the SOX4 
3UTR as has been previously described (Rao et al., 2010). 4 × 105 cells 
HEK293T cells, plated for 24 h, were transfected with either pCDNA or 
pCDNA-miR-132, a -gal expression vector, and a pMiReport vector con-
taining either no 3UTR, the Sox4 3UTR, or a Sox4 3UTR with a mu-
tant miR-132–binding site. 48 h later, cells were lysed using Reporter Lysis 
Buffer (Promega) and luciferase and -gal expression was analyzed, respec-
tively, using a Dual Luciferase kit (Promega) and a chemiluminescent -gal 
reporter kit (Roche).
Immunoblotting. Whole bone marrow samples and bone marrow B cells 
were sorted using the procedure described for RNA preparation using MACS 
columns (Miltenyi Biotec). Whole protein lysates were collected using 
RIPA lysis buffer (Sigma-Aldrich), and were subjected to gel-electrophoresis 
on a mini-PROTEAN TGX gradient (4–15%) gel (Bio-Rad Laboratories), 
and then transferred onto a PVDF membrane. Proteins were detected using 
the following antibodies: anti-Sox4 (154C4a; Abcam), actin-HRP (sc-1616; 
Santa Cruz Biotechnology, Inc.) and goat anti–mouse-IgG-HRP (sc-2005; 
Santa Cruz Biotechnology, Inc.).
Flow cytometry. Respective tissue samples were collected from the appro-
priate mice as indicated in the text, RBC lysed (BioLegend), and processed 
as previously described (Chaudhuri et al., 2012). They were subsequently 
stained with a combination of fluorophore-conjugated antibodies (all from 
BioLegend), such as CD45, B220, CD19, CD43, CD24, IgM, CD11b, 
CD3e, Gr-1, Ter119, Nk1.1, Ly-6C, Sca1, cKit, Flt3, and IL7Ra. Surface 
markers were detected and analyzed using a MACSQuant10 Flow Cytome-
try machine (Miltenyi Biotec). Gating and analysis was performed using 
FlowJo software (Tree Star).
Animals. All experiments were approved by the California Institute of 
Technology Institutional Animal Care and Use Committee. C57BL/6 WT 
and miR-212/132/ mice were bred and housed in the Caltech Office of 
Laboratory Animal Resources (OLAR) facility. Bone marrow reconstitution 
experiments were performed as previously described (Chaudhuri et al., 2012) 
using donor cells from C57BL/6 WT mice or E-myc mice, and with the 
appropriate retroviral vectors as described in the text. In vivo B cell deple-
tion studies were performed by intraperitoneal delivery of 50 µg mouse anti-
CD20 (5D2; Genentech) in 250 µl of PBS. Treated mice were subsequently 
bled at the indicated time points and cell populations in the peripheral blood 
were analyzed using FACS as described above.
RNA-seq data generation and analysis. RNA-seq libraries were pre-
pared from polyA+ selected RNA using the TruSeq RNA Sample Prepara-
tion kit at the Millard and Muriel Jacobs Genetics and Genomics Laboratory 
at Caltech. Libraries were sequenced on the Illumina HiSeq 2500 generating 
single-end 50 bp reads. The refSeq annotation for the mm9 version of the 
mouse genome was used to create a transcriptome Bowtie (version 0.12.7) 
Although this may suggest that Sox4 is a critical target of 
miR-132 in regulating B cell development, the possibility ex-
ists that Sox4 replenishes the B cell pool through an indirect 
mechanism unrelated to the function of miR-132 in B cells. 
The role of Sox4 in B cell development remains poorly un-
derstood. By modulating the expression of miR-132, however, 
we have developed a new tool to study how graded expres-
sion of Sox4 can alter B cell fate decisions. Additionally, Sox4 
is deregulated in several cancer cell lines, including being up-
regulated in certain myelomas, and has been shown to pro-
mote the development of myeloid leukemias (Sandoval et al., 
2012; Tiwari et al., 2013; Zhang et al., 2013). We found that 
enforced expression of Sox4, even in the presence of miR-
132, led to myeloid and B cell lymphomas.
We have thus identified miR-212/132 as a novel player 
in regulating B cell development. Although much remains to 
be understood about the role of miR-212/132 in pro–B cell 
differentiation, we have identified a novel target for miR-
212/132 in Sox4, and together these findings provide unique 
insight into the posttranscriptional mechanisms that govern 
B cell fate. Furthermore, our current work also suggests a 
potential role for miR-212/132 in combating cancers of 
B cell origin.
MATERIALS AND METHODS
DNA constructs. For in vivo miR-132 expression and Sox4 shRNA ex-
periments, we cloned either the mature miR-132 or Sox4 shRNA sequence 
in the microRNA-155 loop-and-arms format (O’Connell et al., 2010a) and 
into the MSCV-eGFP (MG) vector. For Sox4 rescue experiments, Sox4 
lacking its 3UTR was cloned into the MSCV-IRES-eGFP (MIG) vector 
using a previously described strategy (Rao et al., 2010). Sox4 shRNA target 
sequences are listed in Table S2.
For luciferase assays, the microRNA-132 expression cassette was sub-
cloned into the pCDNA3 vector. The 3UTR of Sox4 containing either the 
intact or mutated miR-132–binding site was cloned immediately downstream 
of luciferase in the pMiReport vector as previously described (Chaudhuri 
et al., 2012).
Cell culture. Cells were cultured in a sterile incubator that was maintained 
at 37°C and 5% CO2. HEK293T cells were cultured in DMEM supplemented 
with 10% FBS, 100 U/ml penicillin, and 100 U/ml streptomycin. Primary 
splenic B cells were cultured in complete RPMI supplemented with 10% 
FBS, 100 U/ml penicillin, 100 U/ml streptomycin, 50 µM -mercaptoethanol, 
and the indicated stimulants. All stimulants, including anti-IgM (goat F(ab)2 
anti-mouse IgM; Southern Biotech), lipopolysaccharide (055:B5; Sigma- 
Aldrich), CpG (ODN 1826; Invivogen), mouse IL-4 (BioLegend), mouse 
CD40 ligand (eBioscience), phorbol-12-myristate-13-acetate (PMA; EMD 
Millipore), and ionomycin (EMD Millipore), were prepared as per manufac-
turer’s instructions and used at the concentration indicated in the text. For 
proliferation assays, the WST-1 cell proliferation reagent (Roche) was used 
as per manufacturer’s protocol.
Cell sorting for RNA extraction. For miR-132 expression studies, we 
sorted cells either using MACS columns (Miltenyi Biotec) or by FACS. To 
isolate B cells, RBC-depleted bone marrow or spleen samples were sorted 
on MACS columns. In brief, bone marrow or spleen cells were incubated 
first with biotin-conjugated CD19 (positive selection) or CD43 (negative 
selection) antibodies (BioLegend) in MACS sorting buffer (Miltenyi Biotec), 
followed by incubation with streptavidin-conjugated magnetic beads (Milt-
enyi Biotec) as per manufacturer’s protocol, before being separated on the 
columns. For profiling studies on B cell progenitors, cells were sorted on a 
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